Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AVADEL PHARMACEUTICALS PLC Director's Dealing 2016

Dec 17, 2016

31920_dirs_2016-12-16_5f0b9195-af17-4e35-a0dc-91beb7e94313.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: FLAMEL TECHNOLOGIES SA (FLML)
CIK: 0001012477
Period of Report: 2016-12-14

Reporting Person: GUSKY DAVID P (See Remarks)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-12-14 ADSs A 2000 Acquired 2000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-12-14 Stock Option (right to buy) $10.40 A 14000 Acquired 2016-12-14 ADSs (14000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $7.85 2026-03-02 ADSs (50000) 50000 Direct

Footnotes

F1: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts. The securities acquired as reported in this statement represent the grant of ADSs under the issuer's "Free Share" award program; no purchase price was applicable to such grant. See footnote (2) for details as to the dates such ADSs will be issued to the reporting person.

F2: Represents 2,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.

F3: Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 03/02/2016 grant date.

F4: Options become exercisable as to 3,500 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.